麻豆传媒

Meeting Coverage >

ASCO

Psychosocial Interventions Help Cancer Patients Cope

Programs focus on lowering fear of recurrence, managing advanced disease

ASCO: Healthy Lifestyle Adds to Colon Cancer Survival

Study results should not be interpreted as substitutes for standard care

ASCO: HPV Vax Averts Oral Infections in Young Adults

But low uptake did limit impact

New Standard for Older Patients With Glioblastoma

Radiation plus temozolomide extends survival

Pembrolizumab Plus Lenalidomide Gets Response in MM

Combo shows signs of benefit in relapsed/refractory myeloma

Novel Agent Promising in Pretreated Myeloma

Phase II trial shows 18-month median survival with isatuximab

Plitidepsin Shows Activity in Multiple Myeloma

Early data favorable for sea squirt drug

Practice Changer: Tandem Transplant for Neuroblastoma

13% absolute increase in 3-year event-free survival

New Trial 'Justifies' FDA Nod for Ibrance

Phase III study had almost identical results as pivotal trial

Widely Used Breast Chemo Regimen Falls Short

Taxane-cyclophosphamide regimens fail against taxane-anthracycline combinations

Study: Minorities Less Likely to Get Ca Risk Management

Less genetic testing, bilateral mastectomy in black BRCA carriers

Novel App Seems to Extend Lung Cancer Survival

Web app offers early detection of relapse, complications between healthcare visits

Combo Boosts PFS in Tough-to-Treat Myeloma

Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone

Revlimid Maintenance Benefits Multiple Myeloma

Prolonged overall survival in patients post-autologous stem cell transplant

Longer Letrozole Equals Less BRCA Recurrence

Study suggests that 10 years is better than five

Antibody Shines in Advanced Gastric Cancer

IMAB362 leads to longer remission, better survival

Novel Agent Offers Hope in Small Cell Lung Cancer

Antibody-drug conjugate Rova-T looks good, but in very early trial

ASCO: Extended Femara Therapy Ups DFS in Breast Cancer

Video discusses study showing AI benefit to 10 years

Gemcitabine-Capecitabine Tx: The New Standard in Pancreatic Ca?

Five-year survival reaches all-time high in post-surgical patients

Adjuvant Chemo a Winner in Rare Brain Cancer

Significant survival bump in nondeleted anaplastic glioma

Trastuzumab Biosimilar Shows Similar Effects

Near-copy of Herceptin may improve global access to treatment

Palliative Care Benefits Caregivers, Too

Better QoL, less depression among 'downstream' effects

Transplant Remains King for New Myeloma

Significant improvement in PFS versus systemic treatment

Bone Drugs Equal as Breast Cancer Therapies

Little difference seen among bisphosphonates as cancer fighters.

How ASCO'S First Clinical Trial -- TAPUR -- Came To Be

ASCO's entry will evaluate off-label use of targeted agents

ASCO: Gazyva Doubles Average Remission Time in NHL

Obinutuzumab delays progression in rituximab-refractory indolent disease.

Ibrance Delivers in Advanced Breast Ca

Palbociclib-fulvestrant combo leads to better PFS as second-line therapy

ASCO: Annual Meeting Emphasizes Advances, Challenges in Cancer

Largest program to date highlights developments in breast cancer, other malignancies

ASCO: Chemo-ADT Combo Still Winning in Prostate Cancer

Yet another report of survival improvement with upfront docetaxel plus hormonal therapy.

ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

ASCO: Targeting PD-1 Works in Advanced Melanoma

CHICAGO -- Two studies indicate that using investigative immunotherapy drugs improves survival and response in patients with metastatic melanoma, researchers said here.

ASCO: Antibody Adds 6 Weeks to Squamous NSCLC Survival

CHICAGO -- The novel anti-EGFR monoclonal antibody necitumumab modestly improved survival in squamous non-small cell lung cancer (NSCLC) in a pivotal trial, but many called the effect too small to count.

ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

ASCO: Ipilimumab Cuts Relapse but Safety Issues Remain

CHICAGO -- High-risk melanoma patients have a reduced level of relapse if they are taking the monoclonal antibody ipilimumab (Yervoy) when compared with placebo, researchers said here.

ASCO: Vinegar Test May Reduce Cervical Ca Deaths

CHICAGO -- Vinegar has been used for everything from cleaning refrigerators to taming foot odors, and now this common kitchen staple may reduce cervical cancer deaths as well, researchers reported here.

ASCO: Targeted Agent Has Slim NSCLC Benefit

CHICAGO -- The novel kinase inhibitor nintedanib may slightly delay relapse of non-small cell lung cancer when added to chemotherapy, with perhaps greater benefit in adenocarcinomas, the LUME-Lung 1 trial showed.

ASCO: Herpes-Derived Tx for Melanoma?

CHICAGO -- Intralesional injection of an oncolytic therapy significantly increased the durable response rate in advanced melanoma compared with a control therapy, according to results of a randomized trial.

ASCO: Immune Therapy Durable in Melanoma

CHICAGO -- A therapy aimed at reviving the immune response to advanced melanoma generated durable responses in long-term follow-up of an early clinical trial, a researcher said here.

ASCO: Targeted Rx Slows Ovarian Ca Progression

CHICAGO -- Adding the oral anti-angiogenesis drug pazopanib (Votrient) to chemotherapy extended disease-free survival by an average of 5.6 months, a phase III study showed.

5